NCT07160400

A Study of IBI3032 in Chinese Healthy Participants and Participants With Overweight or Obesity

A Phase 1 Clinical Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IBI3032 After a Single Ascending Dose in Healthy Participants and After Multiple Ascending Doses in Participants With Overweight or Obesity

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 104 (estimated)
• Sponsor: Innovent Biologics Technology Limited (Shanghai R&D Center) · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

This is a randomized, double-blind, placebo-controlled phase 1 clinical study evaluating the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of a single ascending dose of IBI3032 in healthy participants and multiple ascending doses of IBI3032 in participants with overweight or obesity. It consists of 2 parts: Part A is a single ascending dose (SAD) study in healthy participants, and Part B is a multiple ascending dose (MAD) study in participants with overweight or obesity during the 4-week treatment period.

Conditions

• Part A: Healthy Part B: Overweight or Obesity

Interventions

Type	Name	Description
DRUG	Placebo	Single dose placebo IBI3032 administered orally
DRUG	IBI3032 tablets	Single dose of IBI3032 administered orally

Timeline

• Start date: 2025-09-04
• Primary completion: 2026-05-29
• Completion: 2026-09-30
• First posted: 2025-09-08
• Last updated: 2026-04-08

Locations

1 site across 1 country: China